January 4, 2021
The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.
Year
2020
Assets in this page
Download assets
- pdf file
Current Report ESPI 01/2021
Download